Comparing clinical outcomes for a twelve-month trial of zotarolimus- and everolimus-eluting stents in patients with coronary artery disease: data from the THCRIC registry
Open Access
- 7 February 2016
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 10 (4) , 206-213
Abstract
New-generation coronary stents including zotarolimus- and everolimus-eluting stents (ZES and EES) have been shown to decrease the risk of restenosis. The purpose of this study was to compare the safety and efficacy of ZES and EES over a 12-month clinical follow up, in routine clinical practice. This is an observational study in which 1029 consecutive patients treated with ZES (n = 669) or EES (n = 360) were enrolled. The study endpoint was major adverse cardiac events (MACE), defined as cardiac death, nonfatal myocardial infarction (MI), and target lesion or vessel revascularization at 12 months. Follow up was completed among 94.9% of the patients. The overall MACE occurred in 4 (0.6%) and 7 (2.0%) patients in the ZES and EES group, respectively. The occurrence of other cardiac events including nonfatal MI and target vessel or lesion revascularization was 1 (0.2%) versus 1 (0.3%) and 7 (1.1%) versus 5 (1.4%), respectively, in the ZES and EES groups of patients. Despite a slightly lower rate of MACE and cardiac death in the ZES group, the difference between these two groups was not significant (n = 0.064 for overall MACE, p = 0.129 for cardiac mortality, n = 0.999 for nonfatal MI, n = 0.468 for target vessel and n = 0.999 for target lesion revascularization). According to our results, it could be concluded that the difference in the rate of MACE between the ZES and EES groups was not statistically significant at 12-month follow up.Keywords
This publication has 28 references indexed in Scilit:
- Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V StentsJACC, 2013
- A History of Prior Bare Metal Stent Restenosis Is Associated with Major Adverse Cardiac Events in Subsequent Bare Metal Stenting of de novo Coronary LesionsCardiology, 2010
- Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary StentsNew England Journal of Medicine, 2010
- Review: The safety of drug-eluting stentsTherapeutic Advances in Cardiovascular Disease, 2008
- Randomized controlled trials do not reflect reality: Real-world analyses are critical for treatment guidelines!The Journal of Thoracic and Cardiovascular Surgery, 2006
- Drug-Eluting Stents Versus Bare Metal Stents in Percutaneous Coronary Interventions (A Meta-Analysis)The American Journal of Cardiology, 2005
- Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitusJACC, 2005
- Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantationJACC, 2005
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery LesionsCirculation, 2003